Callodine Capital Management LP Has $23.67 Million Stake in GSK plc (NYSE:GSK)

Callodine Capital Management LP lifted its holdings in shares of GSK plc (NYSE:GSK) by 15.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 700,000 shares of the pharmaceutical company’s stock after purchasing an additional 95,000 shares during the period. GSK accounts for about 4.9% of Callodine Capital Management LP’s portfolio, making the stock its 5th biggest position. Callodine Capital Management LP’s holdings in GSK were worth $23,674,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Dodge & Cox grew its position in shares of GSK by 0.5% during the 4th quarter. Dodge & Cox now owns 68,440,912 shares of the pharmaceutical company’s stock worth $2,314,672,000 after buying an additional 353,749 shares during the period. FMR LLC boosted its stake in GSK by 82.1% during the fourth quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company’s stock worth $1,786,475,000 after acquiring an additional 23,814,104 shares in the last quarter. Primecap Management Co. CA grew its holdings in GSK by 70.1% in the fourth quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company’s stock worth $854,349,000 after purchasing an additional 10,407,905 shares during the period. Fisher Asset Management LLC increased its stake in GSK by 1.4% in the fourth quarter. Fisher Asset Management LLC now owns 18,836,797 shares of the pharmaceutical company’s stock valued at $637,061,000 after purchasing an additional 259,867 shares in the last quarter. Finally, Mondrian Investment Partners LTD raised its holdings in shares of GSK by 17.6% during the fourth quarter. Mondrian Investment Partners LTD now owns 5,838,384 shares of the pharmaceutical company’s stock valued at $205,920,000 after purchasing an additional 874,004 shares during the period. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Price Performance

Shares of NYSE:GSK opened at $35.92 on Friday. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.93. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. The stock has a market cap of $74.10 billion, a PE ratio of 22.59, a price-to-earnings-growth ratio of 1.12 and a beta of 0.56. The stock’s fifty day simple moving average is $37.44 and its two-hundred day simple moving average is $36.14.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. As a group, analysts forecast that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, April 10th. Stockholders of record on Friday, February 21st were given a dividend of $0.3932 per share. The ex-dividend date was Friday, February 21st. This is a positive change from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a dividend yield of 4.38%. GSK’s dividend payout ratio (DPR) is currently 100.63%.

Analyst Upgrades and Downgrades

GSK has been the subject of a number of research analyst reports. StockNews.com lowered GSK from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Morgan Stanley began coverage on GSK in a research report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Finally, BNP Paribas began coverage on GSK in a report on Tuesday. They issued a “neutral” rating and a $35.25 target price on the stock. Eight analysts have rated the stock with a hold rating, one has issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $40.58.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.